Yum China Holdings Inc (YUMC) Stock Price Today
Aura AI Summary
Key Stats
- $17.31BMarket Cap
- 2,025,996Volume
- Consumer CyclicalSector
- $57.9552W High
- $39.9852W Low
- 79 DaysTypical Hold Time
- $19.37BEnterprise Value
- 2.25%Div Yield
- 86% Sell | 14% BuyTrading Activity
Track Yum China Holdings Inc (YUMC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Yum China Holdings Inc has traded between a low of $39.98 and a high of $57.95, highlighting its annual price range. Buy and sell Yum China Holdings Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Most Recent News
BNL aims for pre-tax RONE above 20% by 2030 through strategic growth and digital transformation.
BNL, part of BNP Paribas, is accelerating its growth strategy with a focus on high-value client services in Corporate Banking, Private Banking, and Wealth Management. It plans to enhance profitability by investing in digitalization, AI, and employee ...

BNL aims for over 20% pre-tax RONE by 2030 through strategic repositioning and investment in high-value activities.
BNL, part of BNP Paribas, is accelerating its growth with a strategic focus on high-value client activities like Corporate Banking, Private Banking, and Wealth Management. It plans to improve operational efficiency through digitalization and AI, inve...

Safety committee approves dose increase to 15 mg/kg in Entrada's Duchenne muscular dystrophy trial
Entrada Therapeutics announced that an independent safety committee recommended increasing the dose to 15 mg/kg for Cohort 3 in their Phase 1/2 ELEVATE-45-201 trial targeting Duchenne muscular dystrophy. This follows the completion of Cohort 2 at 10 ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.